Health Catalyst (NASDAQ:HCAT) Stock Rating Reaffirmed by Cantor Fitzgerald

Health Catalyst (NASDAQ:HCAT)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports. They presently have a $16.00 target price on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 107.79% from the company’s previous close.

HCAT has been the subject of a number of other research reports. Evercore ISI reduced their target price on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday, July 9th. Piper Sandler reduced their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. JPMorgan Chase & Co. lifted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, Stephens reduced their target price on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.42.

Health Catalyst Stock Performance

HCAT opened at $7.70 on Friday. The company has a fifty day moving average of $7.43 and a two-hundred day moving average of $6.90. The stock has a market capitalization of $454.57 million, a price-to-earnings ratio of -4.16 and a beta of 1.32. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same period in the prior year, the company posted ($0.21) EPS. The business’s quarterly revenue was up 3.7% on a year-over-year basis. On average, equities research analysts forecast that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Transactions at Health Catalyst

In related news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, COO Daniel Lesueur sold 8,137 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the transaction, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,153 shares of company stock valued at $216,004. 2.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HCAT. Nisa Investment Advisors LLC boosted its stake in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after acquiring an additional 5,232 shares in the last quarter. Quarry LP grew its stake in Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares during the last quarter. Perfromance Wealth Partners LLC acquired a new position in Health Catalyst during the second quarter worth approximately $64,000. Mackenzie Financial Corp purchased a new stake in Health Catalyst in the second quarter valued at approximately $70,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Health Catalyst in the first quarter valued at approximately $98,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.